Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Reviparin sodium"'
Autor:
J, Graf, U, Janssens
Publikováno v:
Current Pharmaceutical Design. 10:375-386
A growing body of evidence suggests that low molecular weight heparin (LMWH) is at least as effective as unfractionated heparin (UFH) in the medical management of acute coronary syndromes (ACS) including acute myocardial infarction. Several studies s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18f4105a676ce44071fb24fa7dbe6547
https://doi.org/10.2174/1381612043453342
https://doi.org/10.2174/1381612043453342
Autor:
Anthony K.C. Chan, Maureen Andrew, Michael Gent, Patricia Massicotte, Jim A. Julian, Velma Marzinotto, Peter Bacher, Steven Kohne, Barbara Szechtman, Karen Shields, Steven Shepherd
Publikováno v:
Thrombosis Research. 109:93-99
Introduction: The low molecular weight heparin (LMWH), reviparin–sodium was studied in dose-finding and pharmacokinetic studies in children with central venous lines (CVLs). Materials and methods: The dose-finding study was performed in 24 patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea3c8096340fcc2374e597be00c0a78f
https://doi.org/10.1016/s0049-3848(03)00100-2
https://doi.org/10.1016/s0049-3848(03)00100-2
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis. 8:337-345
Periprocedural and postprocedural anticoagulation during arterial reconstructive surgery (ARS) with intravenous heparin is standard of care. The general use and correct dosage of low-molecular-weight heparin, however, are still under debate. A prospe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ce863c1ac320e3d8b47bbe022e6c2ca
https://doi.org/10.1177/107602960200800405
https://doi.org/10.1177/107602960200800405
Autor:
Hans Klaus Breddin
Publikováno v:
Expert Opinion on Pharmacotherapy. 3:173-182
Reviparin sodium (Clivarine), Knoll AG) is a low molecular weight heparin (LMWH) with a mean peak molecular weight of 3900 Da. It is characterised by a narrow molecular weight distribution profile, with an anti-factor Xa (anti-Xa):anti-factor IIa (an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3608e61e600ecbd34a5f4cdc751dae16
https://doi.org/10.1517/14656566.3.2.173
https://doi.org/10.1517/14656566.3.2.173
Autor:
Ute Klinkhardt, Carl M. Kirchmaier, Hans Klaus Breddin, Dagmar Westrup, Sebastian Harder, Hans-Ulrich Esslinger, Jochen Graff
Publikováno v:
British Journal of Clinical Pharmacology. 52:297-305
Aims The objective of our study was to define the interaction between either unfractionated heparin (UFH) or a low molecular weight heparin, reviparin (REV), and the pharmacodynamic profile of the GPIIb/IIIa-antagonists abciximab (ABC) or tirofiban (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2da2bb0d058dd4f944dca3f21fc60ab
https://doi.org/10.1046/j.0306-5251.2001.01446.x
https://doi.org/10.1046/j.0306-5251.2001.01446.x
Autor:
Peter Griss, T. Wirth, Berthold Schneider, Hakan Tüylü, Rudolf Egbring, Frank Misselwitz, Michael Lomb
Publikováno v:
Arthroscopy: The Journal of Arthroscopic & Related Surgery. 17:393-399
Purpose: Deep venous thrombosis (DVT) is a common, important complication of major orthopaedic surgery, particularly knee arthroplasty. Knee arthroscopy is increasingly performed on an outpatient basis. Few reports have elucidated the incidence of ve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0a1d484f3ea376d416da005a72c6a79
https://doi.org/10.1053/jars.2001.21247
https://doi.org/10.1053/jars.2001.21247
Publikováno v:
New England Journal of Medicine. 344:626-631
Low-molecular-weight heparins are frequently used to treat venous thromboembolism, but optimal dosing regimens and clinical outcomes need further definition.In this multicenter, open-label study with blinded adjudication of end points, we randomly as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95d76f6bfef58abd4084d01f31dc5890
https://doi.org/10.1056/nejm200103013440902
https://doi.org/10.1056/nejm200103013440902
Publikováno v:
Drugs. 61:1185-1209
UNLABELLED Reviparin (reviparin sodium) is a low molecular weight heparin (LMWH) that catalyses the inactivation of factors Xa and IIa by binding to antithrombin, which ultimately leads to the inhibition of the clotting cascade. It is administered su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ad392dd320fa478063478ef8f9b135f
https://doi.org/10.2165/00003495-200161080-00017
https://doi.org/10.2165/00003495-200161080-00017
Autor:
Jeffrey S. Ginsberg, Marilyn Johnston, Roberta Crowther, Mark Crowther, Karen A. Spitzer, Jim A. Julian, Carl A. Laskin
Publikováno v:
Thrombosis Research. 98:133-138
Anticoagulant therapy during pregnancy is problematic. Patients are frequently treated with long-term low-molecular weight heparin despite a lack of evidence for its effectiveness, and in the absence of validated dosing recommendations. The objective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7e6a90536ade8285665005f7e0c23f3
https://doi.org/10.1016/s0049-3848(99)00228-5
https://doi.org/10.1016/s0049-3848(99)00228-5
Autor:
Sebastian Harder, Andreas Kalatzis, Ute Klinkhardt, Hans Klaus Breddin, Heinz Ulrich Esslinger, Silvia Haas
Publikováno v:
British Journal of Clinical Pharmacology. 49:337-341
AimsTo investigate potential interactions between reviparin and acetylsalicylic acid (ASA 300 mg o.d. from day 1–5). MethodsIn an open, randomized, three-way-cross over study nine healthy volunteers received reviparin (s.c. injection of 6300 anti-X
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48d62c4ad76d08d763a7bfc433a6f78b
https://doi.org/10.1046/j.1365-2125.2000.00173.x
https://doi.org/10.1046/j.1365-2125.2000.00173.x